| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | 窒素含有置換基を有するポリマー結合多環式芳香族炭化水素 | JP2014540394 | 2012-10-30 | JP2015502420A | 2015-01-22 | セシル パスキエ，; パトリック ウィス， |
| 本発明は、一般式(1)のポリマー結合多環式芳香族炭化水素化合物に関する:(P−O)x−Q−(Y)w(1)[式中、Pは、置換されていてもよいフェニル環を含む少なくとも3個の繰返し単位を有する重合体部分を表し、Qは、ペリレン、クアテリレン、又はテリレン部分を表し、Yは、(i)ハロゲン、及び(ii)3〜約8個の環員を有し、N原子を介してQに結合している置換されていてもよいN−ヘテロ脂環式基から選択され、ただし、少なくとも1つのYは(ii)を表し、xは1〜4の整数を表し、wは1〜4の整数を表す]。本発明は、このような化合物を作製するプロセス、及びマーキング又はセキュリティ機能を作製するのに使用することができる印刷インキ組成物におけるその使用にさらに関する。 | ||||||
| 22 | Synthesis of substituted salicylic aldehyde derivative | JP2013530310 | 2011-09-22 | JP2013542193A | 2013-11-21 | ジェイ ジェイ． ファーマー，; ガブリエル イー． ジョブ， |
| 本発明は、特に、次に示す工程を含む、サリチルアルデヒド誘導体を合成する方法を包含する：ａ）サリチルアルデヒドまたはその誘導体を提供する工程、ｂ）提供されたサリチルアルデヒド化合物のアンヒドロ二量体を形成する工程、ｃ）アンヒドロ二量体において１以上の化学変換を行う工程、およびｄ）アンヒドロ二量体を加水分解して、工程（ａ）で提供されたものと異なるサリチルアルデヒド誘導体を提供する工程。 本発明は、新規のサリチルアルデヒド二量体を含む、合成物を提供する。 | ||||||
| 23 | A charge control agent and toner using the same | JP2013523427 | 2013-01-30 | JP5329010B1 | 2013-10-30 | 育夫 木村; 一徳 辻; 雅也 東條; 昌史 浅貝 |
| The present invention provides a charge control agent which contains, as an active ingredient, one or more pyridine dicarboxylic acid derivatives represented by general formula (1). (In general formula (1), R1, R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom or the like; R4 and R5 may be the same as or different from each other, and each represents a hydrogen atom or the like; R6 and R7 may be the same as or different from each other, and each represents an optionally substitute cycloalkyl group having 5-10 carbon atoms, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted condensed polycyclic aromatic group. In this connection, R1, R2 and R3 may combine with respective adjacent groups to form a ring.) | ||||||
| 24 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | EP15840612 | 2015-09-10 | EP3191449A4 | 2018-04-25 | CHEUNG MUI; DEMARTINO MICHAEL P; EIDAM HILARY SCHENCK; GUAN HUIPING AMY; QIN DONGHUI; WU CHENGDE; GONG ZHEN; YANG HAIYING; YU HAIYU; ZHANG ZHILIU |
| This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity. | ||||||
| 25 | POLYMER-BONDED POLYCYCLIC AROMATIC HYDROCARBONS HAVING NITROGEN CONTAINING SUBSTITUENTS | EP12780728.7 | 2012-10-30 | EP2776519B1 | 2016-06-22 | PASQUIER, Cécile; WYSS, Patrick |
| A polymer-bonded polycyclic aromatic hydrocarbon compound of general formula (1): (P—O)x-Q-(Y)w (1) wherein P represents a polymeric moiety having at least three repeating units which comprise an optionally substituted phenyl ring; Q represents a perylene, quaterrylene or terrylene moiety; Y is selected from (i) halogen and (ii) optionally substituted N-heterocycloaliphatic groups having from 3 to about 8 ring members which are bonded to Q through an N atom, provided that at least one Y represents (ii); x represents an integer of from 1 to 4; w represents an integer of from 1 to 4. Also, are provided processes of producing the compounds, polymers, markings and articles, and methods of authenticating. | ||||||
| 26 | POLYMER-BONDED POLYCYCLIC AROMATIC HYDROCARBONS HAVING NITROGEN CONTAINING SUBSTITUENTS | EP12780728.7 | 2012-10-30 | EP2776519A1 | 2014-09-17 | PASQUIER, Cécile; WYSS, Patrick |
| A polymer-bonded polycyclic aromatic hydrocarbon compound of general formula (1): (P—O)x-Q-(Y)w (1) wherein P represents a polymeric moiety having at least three repeating units which comprise an optionally substituted phenyl ring; Q represents a perylene, quaterrylene or terrylene moiety; Y is selected from (i) halogen and (ii) optionally substituted N-heterocycloaliphatic groups having from 3 to about 8 ring members which are bonded to Q through an N atom, provided that at least one Y represents (ii); x represents an integer of from 1 to 4; w represents an integer of from 1 to 4. Also, are provided processes of producing the compounds, polymers, markings and articles, and methods of authenticating. | ||||||
| 27 | POLYCARBONATE-POLYESTER COMPOSITION AND ARTICLE | EP15742439.1 | 2015-07-08 | EP3177686A1 | 2017-06-14 | PARIMAL, Kumar; GRIESHABER, Sarah |
| A composition includes specific amounts of a polyester with 1,4 cyclohexanedimethylene terephthalate repeat units, a halogen-free aromatic polycarbonate, a brominated aromatic polycarbonate, and an unsubstituted or substituted C2 C18 hydrocarbyl sulfonate salt. The composition exhibits an improved balance of flame retardancy and transparency relative to a corresponding composition without the sulfonate salt. The composition can be used to fabricate articles that benefit from its transparency and flame retardancy | ||||||
| 28 | SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF | EP14861394 | 2014-11-14 | EP3068394A4 | 2017-04-26 | COPP JAMES DENSMORE; NEWMAN ANN W; LUONG ANNE |
| Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. | ||||||
| 29 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | EP11827530 | 2011-09-22 | EP2618662A4 | 2015-01-21 | FARMER JAY J; JOB GABRIEL E |
| Among other things, the present invention encompasses methods of synthesizing salicylaldehyde derivatives comprising the steps of: a) providing salicylaldehyde or a derivative thereof, b) forming an anhydro dimer of the provided salicylaldehyde compound, c) performing one or more chemical transformations on the anhydro dimer and d) hydrolyzing the anhydro dimer to provide a salicylaldehyde derivative different from that provided in step (a). | ||||||
| 30 | MODIFIED CYCLODEXTRINS FOR THE SELECTIVE SEQUESTRATION OF FENTANYL RELATED COMPOUNDS AND USES THEREOF | US15630869 | 2017-06-22 | US20180371110A1 | 2018-12-27 | Daniel Joseph KENNEDY; Brian P. MAYER; Carlos A. VALDEZ |
| Novel thioalkylcarboxylate-modified CDs and pharmaceutical compositions comprising these thioalkylcarboxylate-modified CDs are disclosed, as well as methods of using the disclosed thioalkylcarboxylate-modified CDs and pharmaceutical compositions thereof to neutralize or reduce undesired effects or symptoms associated with one or more fentanyl related compounds in a subject in need thereof. The use of the disclosed thioalkylcarboxylate-modified CDs to detect the presence of one or more fentanyl related compounds in a sample is also disclosed, which comprises contacting the sample with said thioalkylcarboxylate-modified CDs or a composition comprising these CDs. | ||||||
| 31 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | US16024955 | 2018-07-02 | US20180312519A1 | 2018-11-01 | Jay J. Farmer; Gabriel E. Job |
| Among other things, the present invention encompasses methods of synthesizing salicylaldehyde derivatives comprising the steps of: a) providing salicylaldehyde or a derivative thereof, b) forming an anhydro dimer of the provided salicylaldehyde compound, c) performing one or more chemical transformations on the anhydro dimer and d) hydrolyzing the anhydro dimer to provide a salicylaldehyde derivative different from that provided in step (a). | ||||||
| 32 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | US15599401 | 2017-05-18 | US20170334932A1 | 2017-11-23 | Kyle W.H. Chan; Leah Fung; Robert Sullivan; Paul E. Erdman; Frank Mercurio |
| The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided. | ||||||
| 33 | Electronically conductive polymer binder for lithium-ion battery electrode | US14790299 | 2015-07-02 | US09722252B2 | 2017-08-01 | Gao Liu; Shidi Xun; Vincent S. Battaglia; Honghe Zheng; Mingyan Wu |
| A family of carboxylic acid groups containing fluorene/fluorenon copolymers is disclosed as binders of silicon particles in the fabrication of negative electrodes for use with lithium ion batteries. Triethyleneoxide side chains provide improved adhesion to materials such as, graphite, silicon, silicon alloy, tin, tin alloy. These binders enable the use of silicon as an electrode material as they significantly improve the cycle-ability of silicon by preventing electrode degradation over time. In particular, these polymers, which become conductive on first charge, bind to the silicon particles of the electrode, are flexible so as to better accommodate the expansion and contraction of the electrode during charge/discharge, and being conductive promote the flow battery current. | ||||||
| 34 | Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists | US14820488 | 2015-08-06 | US09572794B2 | 2017-02-21 | Heidi E. Hamm; Shaun R. Stauffer; Craig W. Lindsley; Wandong Wen; Summer E. Young; Matthew T. Duvernay; Kayla J. Temple |
| Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition. | ||||||
| 35 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | US13825548 | 2011-09-22 | US20130197223A1 | 2013-08-01 | Jay J. Farmer; Gabriel E. Job |
| Among other things, the present invention encompasses methods of synthesizing salicylaldehyde derivatives comprising the steps of: a) providing salicylaldehyde or a derivative thereof, b) forming an anhydro dimer of the provided salicylaldehyde compound, c) performing one or more chemical transformations on the anhydro dimer and d) hydrolyzing the anhydro dimer to provide a salicylaldehyde derivative different from that provided in step (a). | ||||||
| 36 | POLYMER-BONDED POLYCYCLIC AROMATIC HYDROCARBONS HAVING NITROGEN CONTAINING SUBSTITUENTS | US13673418 | 2012-11-09 | US20130122222A1 | 2013-05-16 | Cecile PASQUIER; Patrick WYSS |
| A polymer-bonded polycyclic aromatic hydrocarbon compound of general formula (1): (P—O)x-Q-(Y)w (1) wherein P represents a polymeric moiety having at least three repeating units which comprise an optionally substituted phenyl ring; Q represents a perylene, quaterrylene or terrylene moiety; Y is selected from (i) halogen and (ii) optionally substituted N-heterocycloaliphatic groups having from 3 to about 8 ring members which are bonded to Q through an N atom, provided that at least one Y represents (ii); x represents an integer of from 1 to 4; w represents an integer of from 1 to 4. Also, are provided processes of producing the compounds, polymers, markings and articles, and methods of authenticating. | ||||||
| 37 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | US12423522 | 2009-04-14 | US20090203683A1 | 2009-08-13 | Frank HIMMELSBACH; Elke LANGKOPF; Stefan BLECH; Birgit JUNG; Thomas METZ; Flavio SOLCA |
| A compound of formula (I) wherein Ra, Rb, Rc, A, B, C, D, and X are as defined herein, or a tautomer, stereoisomer, or salt thereof, particularly a physiologically acceptable salt thereof. In addition, pharmaceutical compositions comprising an effective amount of a compound of formula (I), methods for the treatment or prophylaxis of benign or malignant tumors, diseases of the airways and lungs, polyps, diseases of the gastrointestinal tract, bile duct, gall bladder, kidneys, and skin, and methods for making compounds of formula (I) are disclosed. | ||||||
| 38 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | US11266920 | 2005-11-04 | US20060063752A1 | 2006-03-23 | Frank Himmelsbach; Elke Langkopf; Stefan Blech; Birgit Jung; Thomas Metz; Flavio Solca |
| A compound of formula (I) wherein Ra, Rb, Rc, A, B, C, D, and X are as defined herein, or a tautomer, stereoisomer, or salt thereof, particularly a physiologically acceptable salt thereof. In addition, pharmaceutical compositions comprising an effective amount of a compound of formula (I), methods for the treatment or prophylaxis of benign or malignant tumors, diseases of the airways and lungs, polyps, diseases of the gastrointestinal tract, bile duct, gall bladder, kidneys, and skin, and methods for making compounds of formula (I) are disclosed. | ||||||
| 39 | Amidinoureas | US429917 | 1982-09-30 | US4515718A | 1985-05-07 | Julius Diamond; George H. Douglas |
| A novel method of treating gastrointestinal, spasmolytic and ulcerogenic disorders by the administration of amidinoureas is disclosed. | ||||||
| 40 | 형질감염 중 재배열 (RET) 억제제로서의 신규 화합물 | KR1020177009244 | 2015-09-10 | KR1020170046180A | 2017-04-28 | 청,무이; 데마르티노,마이클피.; 에이댐,힐러리쉔크; 관,히핑에이미; 친,동희; 우,청더; 공,젠; 양,해영; 유,하이유; 장,지리우 |
| 본발명은형질감염중 재배열 (RET) 키나제의억제제인신규화합물, 그를함유하는제약조성물, 그의제조방법, 및위장감수성, 운동성및/또는분비및/또는복부장애또는질환의정상화, 및/또는설사-우세형, 변비-우세형또는교대대변패턴, 기능성복부팽창, 기능성변비, 기능성설사, 상세불명의기능성장 장애, 기능성복부통증증후군, 만성특발성변비, 기능성식도장애, 기능성위십이지장장애, 기능성항문직장통증, 염증성장 질환을포함한모든분류의과민성장 증후군 (IBS), 증식성질환예컨대비소세포폐암, 간세포성암종, 결장직장암, 수질성갑상선암, 여포성갑상선암, 역형성갑상선암, 유두상갑상선암, 뇌종양, 복막강암, 고형종양, 다른폐암, 두경부암, 신경교종, 신경모세포종, 폰히펠-린다우증후군및 신장종양, 유방암, 난관암, 난소암, 이행세포암, 전립선암, 식도및 위식도접합부의암, 담도암, 선암종, 및증가된 RET 키나제활성을갖는임의의악성종양을포함하나, 이에제한되지는않는 RET 기능장애와관련되거나 RET 활성의조정이치료이익을가질수 있는질환과관련된치료를위한, 단독또는조합으로의요법에서의그의용도에관한것이다. | ||||||
QQ群二维码
意见反馈
意见反馈